within Pharmacolibrary.Drugs.ATC.L;

model L01CA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0015,
    k12             = 0.41,
    k21             = 0.41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vinblastine is a vinca alkaloid antineoplastic agent used in the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and Kaposi's sarcoma. It works by inhibiting microtubule formation in mitotic spindle assembly, causing cell cycle arrest and apoptosis. Vinblastine is FDA-approved and widely used as part of combination chemotherapy regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with cancer (various cancers) after intravenous administration.</p><h4>References</h4><ol><li><p>Links, M, et al., &amp; McKeage, MJ (1999). Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. <i>Cancer investigation</i> 17(7) 479–485. DOI:<a href=\"https://doi.org/10.3109/07357909909032857\">10.3109/07357909909032857</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10518192/\">https://pubmed.ncbi.nlm.nih.gov/10518192</a></p></li><li><p>Leyland-Jones, B (2001). Dose scheduling--Herceptin. <i>Oncology</i> 61 Suppl 2 31–36. DOI:<a href=\"https://doi.org/10.1159/000055399\">10.1159/000055399</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11694785/\">https://pubmed.ncbi.nlm.nih.gov/11694785</a></p></li><li><p>Lu, K, et al., &amp; Loo, TL (1983). Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. <i>Cancer research</i> 43(3) 1405–1408. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6825110/\">https://pubmed.ncbi.nlm.nih.gov/6825110</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CA01;
